Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: Selective review and hypothesis

Anticancer Research

Volumn 18, Issue 5 B, 1998, Pages 3709-3715

  Slominski, Andrzej ^a   Paus, Ralf ^b   Mihm, Martin C ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Immunosuppression; Melanogenesis; Progression; Therapy

Indexed keywords

DIMAPRIT; HISTAMINE AGONIST; MELANIN; NORDIMAPRIT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER GROWTH; CELL METABOLISM; DIET RESTRICTION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOTHERAPY; MELANOGENESIS; MELANOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; BROMODEOXYURIDINE; CHEMOTHERAPY, ADJUVANT; HUMANS; MELANINS; MELANOCYTES; MELANOMA; PHOTOCHEMOTHERAPY; PROTECTIVE AGENTS;

EID: 0031696658     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Slominski A, Ross J, Mihm M: Cutaneous melanoma: pathology, relevant prognostic indicators and progression. Brit Med Bull 51: 548-569, 1995.
2. DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practise of Oncology. Philadelphia; Lippincott-Raven Publishers, 1997.
3. Sakai C, Kawakami Y, Law LW, Furumura M, Hearing VJ: Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 7: 83-95, 1997.
4. Demiere M-F and Koh HK: Adjuvant therapy for cutaneous malignant melanoma. J Am Acad Derm 36: 747-764, 1997.
5. Rosenberg SA: The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. Annu Rev Med 47: 481-491, 1996.
6. Livingston PO and Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45: 10-19, 1997.
7. Ravindranath MH and Morton DL: Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest 15: 491-499, 1997.
8. Scott AM and Cebon J: Clinical promise of tumor immunology. Lancet 349: 19-22, 1997.
9. Schadendorf D: Cytokines, autologous cell immunostimulatory, and gene therapy for cancer treatment. In: The Skin Immune System (Bos JD, ed). Boca Raton, CRC Press, 1997, pp 657-659.
10. Bonnekoh B, Bickenbach JR, Roop DR: Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies. Skin Pharmacol 10: 105-125, 1997.
11. Wick M: The chemotherapy of malignant melanoma. J Invest Dermatol 80: 61S-62S, 1983.
12. Slominski A and Goodman-Snitkoff G: DOPA inhibits induced proliferative activity of murine and human lymphocytes. Anticancer Res 12: 753-756, 1992.
13. Josefsson E, Bergquist J, Ekman R, Tarkowski A: Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology 88: 140-146, 1996.
14. Berquist J, Tarkowski A, Ekman R, Ewing A: Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci USA 91: 12912-12916, 1994.
15. Huffnagle GB, Chen G-H, Curtis JL, McDonald RA, Strieter RM, Toews GB: Down-regulation of the afferent phase of T cell-mediated pulmonary inflamation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol 155: 3507-3516, 1995.
16. Slominski A, Paus R, Bomirski A: Hypothesis: a possible role of melatonin receptor in vitiligo. J Royal Soc Med 82: 539-541, 1989.
17. Miranda M, Ligas C, Amicarelli F, Dalessandro E, Brisdelli F, Zarivi O. Poma A: Sister chromatid exchange (SCE) rates in human melanoma cells as an index of mutagenesis. Mutagenesis 12: 233-236, 1997.
18. Miranda M, Botti D, Di Cola M: Possible genotoxicity of melanin synthesis intermediates: tyrosinase reaction products interact with DNA in vitro. Mol Gen Genet 193: 395-399, 1984.
19. Harsanyi ZP, Post P, Brinkmann JP, Chedekel MR, Deibel RM: Mutagenicity of melanin from red hair. Experientia 36: 291-292, 1980.
20. Hill HZ: The relationship of the photobiology of skin cancer and melanins to the radiation biology of melanoma: a selective review. Comments MoI Cell Biophys 6: 141-174, 1989.
21. Lukiewicz S, Pilas B, Nowicka J, Cieszka K, Gurbiel R: Molecular and cellular basis of different radiosensitivity in pigmented and nonpigmented hamster melanoma cells. In: Pigment cell. Phenotypic expression in pigment cells (Seiji M ed). Tokyo, University of Tokyo, 1981, pp 647-653.
22. Rofstad EK, Brustad T, Johannessen JV, Mossige J: Effect of cobalt-60 gamma rays and DTIC (5-(3,3 dimethyl-1-triazeno)-imidazole-r-carboxamide) on human malignant melanomas in athymic nude mice. Br J Radiol 50: 314-320, 1977.
23. Prota G: Melanins and Melanogenesis. New York, Academic Press, 1992.
24. Favilla I, Favilla ML, Gosbell AD, Barry WR, Ellims P, Hill JS, Byrne JR: Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res 5: 355-364, 1995.
25. Slominski A, Paus R, Schanderdorf D: Melanocytes as sensory and regulatory cells in the epidermis. J Theor Biol 164: 103-120, 1993.
26. Protta G: Pigment cell research: what directions? Pigment Cell Res 10: 5-11, 1997.
27. Hori Y, Hearing VJ, Nakayama J, eds. Melanogenesis an Malignant Melanoma: Biochemistry, Cell Biology, Molecular Biology, Pathophysiology, Diagnosis and Treatment. New York, Elsevier, 1996.
28. Prota G: The chemistry of melanins and melanogenesis. Fortchritte der Chem Organischer Naturstoffe 64: 93-148. 1995.
29. Okun MR: The role of peroxidase in neuromelanin synthesis - a review. Physiol Chem Phys Med NMR 29: 15-22, 1997.
30. Chakraborty AK, Platt JL, Kim KK, Kwon BS, Bennette DC, Pawelek J: Polymerization of 5,6-dihydroxyindole 2-carboxylic acid to melanin by the PMEL 17/silver locus. Eur Biochem 236: 180-188, 1996.
31. Moellmann G, Slominski A, Kuklinska E, Lemer AB: Regulation of melanogenesis in melanocytes. Pigment Cell Res Suppl 1: 79-871, 1998.
32. Salopek TG and Jimbow K: Induction of melanogenesis during the various melanoma growth phases and the role of tyrosinase, lysosome-associated membrane proteins, and p90 calnexin in the melanogenesis cascade. J Invest Dermatol Symp Proc 1: 195-202, 1996.
33. Schallreuter KU, Wood JM, Pittelkow MR, Gutlich M, Lemke KR, Rodl W, Swanson NN, Hitsemann K, Ziegler I: Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 263: 1444-1446, 1994.
34. Schallreuter KU, Schulz-Douglas V, Bunz A, Beazley W, Korner C: Pteridines in the control of pigmentation. J Invest Dermatol 109: 31-35, 1997.
35. Axelrod J and Lemer AB: O-methylation in the conversion of tyrosine to melanin. Biochim Biophys Acta 71: 650-655, 1963.
36. Smit NPM, Latter AJM, Naish-Byfield S, Westerhof W, Pavel S, Riley PA: Catechol O-methyltransferase as a target for melanoma destruction. 48: 743-752, 1994.
37. Scislowski PWD and Slominski A: The role of NADP-dependent dehydrogenases in hydroxylation of tyrosine in hamster melanomas. Neoplasma 30: 239-243, 1983.
38. Scislowski PWD, Slominski A, Bomirski A, Zydowo M: Metabolic characterization of three hamster melanoma variants. Neoplasma 32: 593-598, 1985.
39. Wang Y, Aisen P, Casadevall A: Cryptococcus neoformans melanin and virulence: mechanism of action. Inf Immun 63: 3131-3136, 1995.
40. Musso RN, Brenei S, Indiveri F, Lotti G: L-tyrosine and nicotine induce synthesis of L-DOPA and norepinephrine in human lymphocytes. J Neuroimmunol 74: 117-120, 1997.
41. Miranda M, Bonfigli A, Zarivi O, Manilla A, Cimini AM, Arcadi A: Restriction patterns of model DNA treated with 5,6 dihydroxyindole, a potent cytotoxic intermediate of melanin synthesis: effect of u.v. irradiation. Mutagenesis 2: 45-50, 1987.
42. Yamafuji K, Murakami H, Sinozuka M: Antitumor activity of dopa, dopamine, noradrenaline or adrenalin and their reaction with nucleic acids. Z Krebsforsch 73: 195-203, 1970.
43. Moldeus P, Nrdenskjold M, Bolesfoldi G, Eiche A, Haglund U, Bo L: Genetic toxicity of dopamine. Mutation Res 124: 25-34, 1983.
44. Stokes AH, Brown BG, Lee CK, Doolittle DJ, Vrana KE: Tyrosinase enhances the covalent DNA modification by dopamine. Brain Res. Mol Brain Res 42: 167-170, 1996.
45. Husain S and Hadi SM: Strand scission in DNA induced by L-DOPA in the presence of Cu(II). FEBS Lett 364: 75-78, 1995.
46. Cerutti PA: Prooxidant states and tumor promotion. Science 227: 375-381, 1985.
47. Miranda M, Amicarelli F, Poma A, Ragnelli AM, Scirri C, Aimola PP, Masciocco L, Bonfigli A, Zarivi O: Cyto-genotoxic species leakage within human melanoma melanosomes, molecular-morphological correlations. Biochem Mol Biol Int 32: 913-922, 1994.
48. Bomirski A, Slominski A, Bigda J: The natural history of a family of transplantable melanomas in hamsters. Cancer Met Rev 7: 95-119, 1988.
49. Borovansky J, Mirejovsky P, Riley PA: Possible relationship between abnormal melanosome structure and cytotoxic phenomena in malignant melanoma. Neoplasma 38: 393-400, 1991.
50. Slominski A, Paus R, Plonka P, Handjinski B, Maurer M, Chakraborty A, Mihm M: Pharmacological disruption of hair follicle pigmentation as a model for studying the melanocyte response to and recovery from cytotoxic damage in situ. J Invest Dermatol 106: 1203-1211, 1996.
51. Rorsman H, Agrup G, Hansson C, Rosengren. Biochemical recorders of malignant melanoma. In: Pigment Cell (MacKie RM, ed). Basel, Kargel, 1983, Vol 6, pp 93-115.
52. Scislowski PWD, Slominski A, Bomirski A: Biochemical characterization of three hamster melanoma variants. II. Glycolysis and oxygen consumption. Int J Biochem 16: 327-331, 1984.
53. Slominski A, Moellmann G, Kuklinska E, Bomirski A, Pawelek J: Positive regulation of melanin pigmentation by two key substrates of the melanogenic pathway: L-tyrosine and L-dopa. J Cell Sci 89: 287-296, 1988.
54. Slominski A, Moellmann G, Kuklinska E: L-tyrosine, L-dopa and tyrosinase as positive regulators of the subcellular apparatus of melanogenesis in Bomirski Ab amelanotic melanoma. Pigment Cell Res 2: 109-116, 1989.
55. Slominski A and Friedrich T: L-DOPA inhibits in vitro phosphorylation of melanoma glycoproteins. Pigment Cell Res 5: 396-400, 1992.
56. Slominski A and Paus R: Towards defining receptors for L-tyrosine and L-dopa. Mol Cell Endocrinol 99: C7-C 11, 1994.
57. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H: Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73: 629-636, 1994.
58. Karg E, Hultberg B, Isaksson A, Rosenberg E, Rorsman H: Enzyme release from cultured human melanoma cells. Acta Derm Venereol (Stockh) 70: 286-290, 1990.
59. Slominski A and Paus R: Are L-tyrosine and L-dopa hormone-like bioregulators? J Theor Biol 143: 123-138, 1990.
60. Riu J-P, Ariyan S, Brandow KR, Fielding LP: The association between melanoma, lymphoma and other primary neoplasms. Arch Surg 130: 1056-1061, 1995.
61. Barranco SC, Romsdahl MM, Humphrey RM: The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 31: 830-833, 1970.
62. Slominski A and Paus R: Inhibition of melanogenesis for melanoma therapy? J Invest Dermatol 103: 742, 1994.
63. Lerner AB and Fitzpatrick TB: Biochemistry of melanin formation. Physiol Rev 30: 91-126, 1950.
64. Demopoulos HB: Effects of reducing the phenylalanine-tyrosine intake of patients with advanced melanoma. Cancer 16: 657-664, 1966.
65. Demopoulos HB: Effects of low phenylalanine-tyrosine diets on S91 mouse melanoma. J Natl Cancer Inst.37: 185-190, 1966.
66. Jensen A, Ageberg J, Edmund J: The effects of phenylalanine-tyrosine low diet on the growth and morphology of transplanatable malignant melanomas of the Syrian golden hamsters (Mesocricetus auratus). Acta Pathol Microbiol Scand Sect A 81: 559-568, 1973.
67. Mishima Y: A post melanosomal era: control of melanogenesis and melanoma growth. Pigment Cell Res Suppl 2: 3-16, 1992.
68. Mars U and Larsson BS: New thioureas and related substances intended for melanoma targeting. Pigment Cell Res 8: 194-201, 1995.
69. Bolognia JL and Pawelek JM: Biology of hypopigmentation. Am J Acad Derm 19: 217-255, 1988.
70. Kawagishi H, Somoto A, Kuranari J, Kimura A, Chiba S: A novel cyclotetrapetide produced by lactobactillus helveticus as a tyrosinase inhibitor. Tetrahedron Lett 34: 3439-3440, 1993.
71. Arai N, Shiomi K, Takamatsu S, Komiyama K, Shinose M, Takahashi Y, Tanaka Y, Iwai Y, Liu JR, Omura S: Amphistin, a new melanogenesis inhibitor, produced by actinomycete. J Antibiot 50: 808-814, 1997.
72. Silagi S and Brace SA: Suppresion of malignancy and differentiation in melanotic melanoma cells. Proc Nat Acad Sci USA 66: 72-78, 1970.
73. Kidson SH and De Haan JB: Effect of thymidine analogs on tyrosinase activity and mRNA accumulation in mouse melanoma cells. Exp Cell Res 188: 36-41, 1990.
74. McEwan MT and Parsons PG: Regulation of tyrosinase expression and activity in human melanoma cells via histamine receptors. J Invest Dermatol 97: 868-873, 1991.
75. Siegrist W and Eberle AN: Melanocortins and their implication in melanoma. Trends Endocrinol Metab 6: 115-120, 1995.
76. Slominski A, Paus R, Wortsman J: On the potential role of proopiomelanocortin in skin physiology and pathology. Mol Cell Endocrinol 93: C1-C6, 1993.
77. Luger TA, Scholzen T, Brzoska T, Becher E, Slominski A, Paus R: Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte stimulating hormone. Ann NY Acad Sci 1998; in press.
78. Slominski A and Pruski D: Melatonin inhibits proliferation and melanogenesis in rodent melanoma cells. Exp Cell Res 206: 189-294, 1993.
79. Slominski A, Chassaleris N, Mazurkiewicz J, Paus R: Murine skin as a target for melatonin bioregulation. Exp Dermatol 3: 45-50, 1994.
80. Brezinski A: Melatonin in humans. New Engl J Med 336: 186-195, 1997.
81. Chen Y-T, Stocken E, Tsang S, Coplan KA, Old LJ: Immunophenotyping of melanoma for tyrosinase: Implications for vaccine development. Proc Natl Acad Sci USA 92; 8125-8129, 1995.
82. Slominski A, Moellmann G, Kuklinska E: MSH inhibits growth in a line of amelanotic hamster melanoma cells and induces increases in cAMP levels and tyrosinase activity without inducing melanogenesis. J Cell Sci 92: 551-559, 1989.
83. Abdallah RM, Starkey JR, Meadows GG: Dietary restriction of tyrosine and phenylalanine: inhibition of metastasis in three rodent tumors. J Natl Cancer Inst 78: 759-769, 1987.
84. Elstad CA and Meadows GG: Modulation of B16-BL6 murine melanoma metastatic phenotype by tyrosine and phenylalanine restriction in the absence of host selection pressure. Anticancer Res 13: 523-528, 1993.